Business
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation\nPRINCETON, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) event to discuss the pathology and growing prevalence of HPV16-positive head and neck squamous cell carcinoma (“HNSCC\") as well as the Company’s upcoming VERSATILE-003 Phase 3 clinical trial of Versamune® HPV + pembrolizumab for first-line treatment of recurrent and/or metastatic HPV16-positive HNSCC. The KOL event will take place on Tuesday, December 17, 2024, at 12 p.m. ET and panel participants include: Francis “Frank” Worden, M.D., Rogel Cancer Center, University of MichiganKevin Harrington, MBBS, Ph.D., The Institute of Cancer Research, United Kingdom The event will be moderated by Kirk Shepard, M.D., PDS Biotech’s Chief Medical Officer. Webcast and Registration Details Date: Tuesday, December 17, 2024Time: 12 p.m. - 1:30 p.m. ETRegistration: Click here About Our Speakers Francis Worden, M.D., is a clinical professor awarded the Nancy Wigginton Oncology Research Professor of Thyroid Cancer endowed chair at the Rogel Cancer Center at the University of Michigan. He is a clinical investigator with the multidisciplinary head and neck cancer and lung cancer teams. Dr. Worden is a leading expert in the treatment of HPV-positive oropharyngeal cancer. He has co-authored over 190 peer-reviewed articles and participated in approximately 20 clinical trials with three ongoing trials in HNSCC, including the VERSATILE-002 trial. Dr. Worden received his medical degree from the Indiana University School of Medicine. He completed a combined internal medicine and pediatrics residency at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In 2000, Dr. Worden joined the University of Michigan Rogel Cancer Center faculty. Kevin Harrington, MBBS, Ph.D., is Head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research in the United Kingdom. Dr. Harrington is a Professor of Biological C...